OBJECTIVE: To probe into the efficacy of safety of domestic and imported voriconazole in the treatment of pulmonary fungal infection after renal transplantation. METHODS: Totally 60 patients with suspected or confirmed pulmonary fungal infection after renal transplantation admitted into the Eighth Medical Center of Chinese PLA General Hospital from Sept. 2018 to May 2020 were retrospectively selected and divided into domestic voriconazole group and imported voriconazole group according to different drug therapy

with 30 cases in each group. Differences in clinical efficacy

incidences of adverse drug reactions

average treatment time and treatment cost were compared between two groups. RESULTS: The total effect of imported voriconazole group was 83. 3%（ 25/30）

which was significantly higher than that of domestic voriconazole group（ 63. 2%

19/30）

with statistically significant difference（ χ2= 5. 08

P = 0. 024）. The incidences of adverse drug reactions of domestic voriconazole group and imported voriconazole group were respectively 13. 3%（ 4/30） and 20. 0%（ 6/30）

the difference had no statistical significance（ χ2= 0. 48

P =0. 49）. The average treatment time of imported voriconazole group was 19. 35 ± 5. 47 days

with the average treatment cost was 35 710. 21 ± 4 762. 18 yuan; the average treatment time of domestic voriconazole group was 21. 47 ± 6. 25 days

with the average treatment cost was 12 248. 05 ± 690. 01 yuan; the treatment cost of imported voriconazole group was significantly higher than that of domestic voriconazole group

with statistically significant difference（ t = 29. 03

P <0. 001）. CONCLUSIONS: For patients with pulmonary fungal infection after renal transplantation

imported voriconazole has better efficacy than domestic voriconazole

while there is no significant difference in safety between two drugs

but the treatment cost of imported voriconazole is significantly higher than that of domestic voriconazole.